Status:
TERMINATED
Ventavis® Registry Protocol
Lead Sponsor:
Actelion
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with...
Detailed Description
The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with...
Eligibility Criteria
Inclusion
- Have a current diagnosis of WHO Group I PAH
- Have initiated therapy with commercial Ventavis® administered via portable nebulizer at least 3 months prior to study enrollment, either with commercial product or from participation in Actelion's Clinical Study AC-063A302
- Age \> or = 18 years old at the time of enrollment
Exclusion
- Meet the criteria for inclusion into WHO Groups II, III, IV or V PAH
- Are not currently on commercial Ventavis®
- Have initiated therapy with commercial Ventavis® administered via portable nebulizer less than 3 months prior to study enrollment
Key Trial Info
Start Date :
March 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT00902603
Start Date
March 1 2009
End Date
February 1 2014
Last Update
February 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.